Then those "scientists" have nothing to worry about, so why are they
avoiding putting their arms where their mouths are?

Then there is no problem, and this can be easily demonstrated by those
who make this claim accepting a dose.

We aren't talking about vaccines, but thanks for offering the first
excuse for running away. it sounds much better than "I won't do it
because I might be wrong".

No babies have all their vaccines in one go, but I have been offering
for years to accept a full up-to-school-age schedule of vaccinations
in one go whenever anyone is ready to arrange it.

Then prove me wrong and demonstrate it is a diversion. Roll up your
sleeve and let's get injecting. Would you like an alcohol wipe first,
or don't you need that, seeing that germs don't exist?

True

I don't know of anyone who says it "causes" but they claim it to be a
precursor.

Yes.

John does not exist. John is really a bot posting bullshit.

Go for it!  Most major medical schools have some HIV research going on.  So
check out the one nearest yourself... march right into their lobby, go to
the receptionist and announce loudly that you wish to be injected with HIV.
Don't be shy... be bold!

If you have trouble finding one in your local area, just tell us where you
live, and I'm sure some kind person will tell you where the closest health
research center is located.

I found lots in Google:
http://www.google.com/search?hl=en&q=university+research+HIV&btnG=Google+Search

Pls explain what you mean by '*purified* HIV'. (experience has shown
that many alt-med folks make up their own definition of things, so we
better get this clear before anything else)

snip

I found the citation and the abstract is below. I'd like to read the
full article.

The abstract at least suggests that this may be due to people being
treated later (CD4 count around 200).

If you have the full article, I'd like to review it. I'd bet that
Hepatitis C co-infection plays a significant role as well as TB.

Other data contradict their findings, seeing a clear decrease in
morbidity and mortality among populations where ARV treatment is
routinely available. See the abstracts that follow.

A few things are quite clear and have been for some time, even with
the rosiest picture of a reduced mortality attributable to ARV.

1) ARV have serious side effects that in a small proportion can even
be fatal;

2) ARV are hideously over-priced, as are most drugs, devices and
diagnostics;

3) Better therapies are needed to manage HIV disease;

4) There is a dearth of research, however, data do underscore that
addressing host-related issues can have a significant contributing
influence on HIV disease outcomes; e.g., the use of a
multivitamin/mineral can reduce the HIV disease progression rate by
30% while reducing morbidity and mortality among people living with
AIDS.
        George M. Carter

***
HIV treatment response and prognosis in Europe and North America in
the first decade of highly active antiretroviral therapy: a
collaborative analysis. M May, J Sterne, D Costagliola, M Egger, C
Sabin, A Phillips, A Justice, F Dabis, J Gill, J Lundgren, R Hogg, F
de Wolf, G Fätkenheuer, S Staszewski, and A d´Arminio Monforte for
The Antiretroviral Therapy (ART) Cohort Collaboration.
Lancet. 2006 Aug 5;368(9534):451-8

BACKGROUND: Highly active antiretroviral therapy (HAART) for the
treatment of HIV infection was introduced a decade ago. We aimed to
examine trends in the characteristics of patients starting HAART in
Europe and North America, and their treatment response and short-term
prognosis. METHODS: We analysed data from 22,217 treatment-naive
HIV-1-infected adults who had started HAART and were followed up in
one of 12 cohort studies. The probability of reaching 500 or less
HIV-1 RNA copies per mL by 6 months, and the change in CD4 cell
counts, were analysed for patients starting HAART in 1995-96, 1997,
1998, 1999, 2000, 2001, and 2002-03. The primary endpoints were the
hazard ratios for AIDS and for death from all causes in the first year
of HAART, which were estimated using Cox regression. RESULTS: The
proportion of heterosexually infected patients increased from 20% in
1995-96 to 47% in 2002-03, and the proportion of women from 16% to
32%. The median CD4 cell count when starting HAART increased from 170
cells per muL in 1995-96 to 269 cells per muL in 1998 but then
decreased to around 200 cells per muL. In 1995-96, 58% achieved HIV-1
RNA of 500 copies per mL or less by 6 months compared with 83% in
2002-03. Compared with 1998, adjusted hazard ratios for AIDS were 1.07
(95% CI 0.84-1.36) in 1995-96 and 1.35 (1.06-1.71) in 2002-03.
Corresponding figures for death were 0.87 (0.56-1.36) and 0.96
(0.61-1.51). INTERPRETATION: Virological response after starting HAART
improved over calendar years, but such improvement has not translated
into a decrease in mortality.

***
Yeni P. Update on HAART in HIV. J Hepatol. 2006;44(1 Suppl):S100-3.
Epub 2005 Nov 28.

Hopital Bichat-Claude Bernard, 46, Rue Henri-Huchard, 75877 Paris
Cedex 18, France. patrick.yeni@bch.ap-hop-paris.fr

Highly active antiretroviral combination therapy (HAART) has been
responsible for a dramatic decrease in AIDS mortality since 1996, and
has changed the clinical profile of HIV infection from a sub-acute
lethal to a chronic ambulatory disease. HAART consists of a double
nucleoside (NRTI) backbone plus either a non-nucleoside reverse
transcriptase inhibitor (NNRTI) or a ritonavir pharmacologically
enhanced protease inhibitor (PI/r). Triple NRTI combinations are less
potent than 2NRTIs/NNRTI or 2NRTIs/PI/r combinations. Antiretroviral
first-line therapy is rapidly moving towards more convenient and less
toxic regimens. Three double NRTI co-formulations are now available,
and the risk of mitochondrial toxicity is low with drugs such as 3TC,
FTC and tenofovir. Similarly, atazanavir, a recently available PI, can
be given once daily and is less metabolically toxic than other PIs.
Antiretroviral salvage therapy takes advantage of the development or
availability of new drugs, either from existing (tipranavir, TMC 114
as new PIs) or new classes (T20 as a fusion inhibitor), that remain
active on many triple-class drug resistant viruses. More progress is
needed in the field of drug discovery, since a significant proportion
of patients still die from AIDS with a multi-resistant virus, and
since the incidence of primary HIV resistance is increasing in various
parts of the world.

***
Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate
mortality among injecting drug users that is not attributable to AIDS.
Sex Transm Infect. 2006 Jun;82 Suppl 3:iii56-63.

National Drug and Alcohol Research Centre, University of New South
Wales, Sydney NSW 2052, Australia. l.degenhardt@unsw.edu.au

BACKGROUND: Injecting drug use (IDU) and associated mortality appear
to be increasing in many parts of the world. IDU is an important
factor in HIV transmission. In estimating AIDS mortality attributable
to IDU, it is important to take account of premature mortality rates
from other causes to ensure that AIDS related mortality among
injecting drug users (IDUs) is not overestimated. The current review
provides estimates of the excess non-AIDS mortality among IDUs.
METHOD: Searches were conducted with Medline, PsycINFO, and the Web of
Science. The authors also searched reference lists of identified
papers and an earlier literature review by English et al (1995). Crude
mortality rates (CMRs) were derived from data on the number of deaths,
period of follow up, and number of participants. In estimating the
all-cause mortality, two rates were calculated: one that included all
cohort studies identified in the search, and one that only included
studies that reported on AIDS deaths in their cohort. This provided
lower and upper mortality rates, respectively. RESULTS: The current
paper derived weighted mortality rates based upon cohort studies that
included 179 885 participants, 1,219,422 person-years of observation,
and 16,593 deaths. The weighted crude AIDS mortality rate from studies
that reported AIDS deaths was approximately 0.78% per annum. The
median estimated non-AIDS mortality rate was 1.08% per annum.
CONCLUSIONS: Illicit drug users have a greatly increased risk of
premature death and mortality due to AIDS forms a significant part of
that increased risk; it is, however, only part of that risk. Future
work needs to examine mortality rates among IDUs in developing
countries, and collect data on the relation between HIV and increased
mortality due to all causes among this group.

***
Severe P, Leger P, Charles M, Noel F, et al. Antiretroviral therapy in
a thousand patients with AIDS in Haiti. N Engl J Med. 2005 Dec
1;353(22):2325-34.
Comment in: N Engl J Med. 2005 Dec 1;353(22):2392-4.

Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections
Opportunistes, Port-au-Prince, Haiti.

BACKGROUND: The one-year survival rate of adults and children with the
acquired immunodeficiency syndrome (AIDS), without antiretroviral
therapy, has been about 30 percent in Haiti. Antiretroviral therapy
has recently become available in Haiti and in other developing
countries. Data on the efficacy of antiretroviral therapy in
developing countries are limited. High rates of coinfection with
tropical diseases and tuberculosis, along with malnutrition and
limited laboratory monitoring of therapy, may decrease the efficacy of
antiretroviral therapy in these countries. METHODS: We studied the
efficacy of antiretroviral therapy in the first 1004 consecutive
patients with AIDS and without previous antiretroviral therapy who
were treated beginning in March 2003 in Port-au-Prince, Haiti.
RESULTS: During a 14-month period, three-drug antiretroviral therapy
was initiated in 1004 patients, including 94 children under 13 years
of age. At enrollment, the median CD4 T-cell count in adults and
adolescents was 131 per cubic millimeter (interquartile range, 55 to
211 per cubic millimeter); in children, a median of 13 percent of T
cells were CD4-positive (interquartile range, 8 to 20 percent).
According to a Kaplan-Meier survival analysis, 87 percent of adults
and adolescents and 98 percent of children were alive one year after
beginning treatment. In a subgroup of 100 adult and adolescent
patients who were followed for 48 to 56 weeks, 76 patients had fewer
than 400 copies of human immunodeficiency virus RNA per milliliter. In
adults and adolescents, the median increase in the CD4 T-cell count
from baseline to 12 months was 163 per cubic millimeter (interquartile
range, 77 to 251 per cubic millimeter). In children, the median
percentage of CD4 T cells rose from 13 percent at baseline to 26
percent (interquartile range, 22 to 36 percent) at 12 months.
Treatment-limiting toxic effects occurred in 102 of the 910 adults and
adolescents (11 percent) and 5 of the 94 children (5 percent).
CONCLUSIONS: This report documents the feasibility of effective
antiretroviral therapy in a large number of patients in an
impoverished country. Overall, the outcomes are similar to those in
the United States. These results provide evidence in support of
international efforts to make antiretroviral therapy available to
patients with AIDS in developing countries. Copyright 2005
Massachusetts Medical Society.

**
Morris A, Masur H, Huang L.Current issues in critical care of the
human immunodeficiency virus-infected patient. Crit Care Med. 2006
Jan;34(1):42-9.
Comment in: Crit Care Med. 2006 Jan;34(1):239-40.

Department of Medicine, Division of Pulmonary and Critical Care
Medicine, Keck School of Medicine, University of Southern California,
Los Angeles, CA, USA.

OBJECTIVE: To provide current information on the epidemiology of human
immunodeficiency virus (HIV)-infected patients admitted to the
intensive care unit during the era of combination antiretroviral
therapy and to review issues related to the administration of
antiretroviral therapy that are relevant to the intensivist. DESIGN:
Review of literature related to intensive care of HIV-infected
patients. RESULTS: Overall mortality of HIV-infected patients in the
intensive care unit has decreased in the era of combination
antiretroviral therapy, and patients are more commonly admitted with
non-HIV-related illnesses. Use of antiretroviral therapy in the
intensive care unit is difficult but may be associated with improved
outcomes. CONCLUSIONS: HIV-infected patients are less likely to be
admitted to the intensive care unit with opportunistic infections but
more likely to be admitted with problems unrelated to HIV infection or
with conditions related to antiretroviral therapy. With current
management strategies, more patients survive intensive care unit
admission. Intensivists need to be familiar with antiretroviral
therapy to recognize life-threatening toxicities unique to these
drugs; to avoid drug interactions, which are extremely common and
potentially life-threatening; and to avoid enhancing HIV drug
resistance, an occurrence that could have devastating consequences for
the patient following intensive care unit discharge.

Your wager. You lose.

What part of prolonged life are we discussion here. How is THIS a
distortion? They either live longer othe they don't.  this is just like
what happened in 1993 with the Concord Study and AZT.

Also look at the latency period from HIV infection to AIDS definning
disease and the cause of death. Many cases are due to liver toxicity.
The drugs have failed again.